All In Biotech

Drug Trial Radar · NCT03322800

A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Oct 23, 2017

Primary completion

Apr 6, 2018

Study completion May 24, 2018

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will characterize the pharmacokinetics (PK) of AK0529, the effect of food and evaluate the safety of AK0529 in healthy Chinese adult subjects. 50 subjects will be randomized to receive a dose level of AK0529 or placebo in five groups. The total study duration will be approximately 18-27 days for each subject.

Conditions

  • Healthy

Interventions

  • AK0529Drug

    Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

  • PlaceboOther

    Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10
  2. Time to Maximum Plasma Concentration (Tmax)Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10
  3. Area under the plasma concentration-time curve from time zero up to time (AUC 0-t)Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10
  4. Terminal Half-Life (t1/2)Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10
  5. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10
  6. Apparent Oral Clearance (CL/F)Time frame: Day1 (pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12 hrs post-dose), Day2 (24 hrs post-dose), Day3 (48 hrs post-dose), Day4 (72 hrs post-dose), Day5, Day6, Day7, Day8, Day9 and Day10
  7. Percentage of Subjects with Adverse Events (AEs)Time frame: From baseline up to approximately 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.